Metabolic & Weight Management
Tirzepatide
A dual incretin receptor agonist acting on both GIP and GLP-1 pathways within physician-directed metabolic care.
- Physician reviewed
- 503A pharmacy compounded
- Patient-specific prescription
Formats & pricing
Dose and pricing for Tirzepatide are confirmed after your physician review, since the titration schedule determines the strength you are prescribed.
Start my CareSee how it worksPricing reflects the compounded preparation and physician review. Final therapy and dosing are determined only after your intake is reviewed.
Overview
What is Tirzepatide?
Tirzepatide is a dual agonist at both the GIP and GLP-1 receptors. Acting on two incretin pathways rather than one, it is evaluated within medical weight management and cardiometabolic programs where appetite regulation and glucose control are both priorities.
Mechanism
How it works
GLP-1 receptor activity reduces appetite and slows gastric emptying, while GIP receptor activity contributes to insulin sensitivity and how fat tissue handles nutrients. Together the two pathways address both intake and metabolic handling of what is eaten.
Wellness support
Potential wellness support areas
These areas are commonly discussed within wellness-focused protocols. They are educational statements, not medical claims or guarantees of outcome.
- Physician-directed weight management
- Appetite regulation and satiety
- Insulin sensitivity and glycemic markers
- Cardiometabolic risk factors reviewed with labs
Administration
Format & dosing
A once-weekly subcutaneous injection with a stepwise titration schedule. Dose increases are spaced to allow tolerance to build, and your physician determines when and whether to escalate.
Labs & monitoring
Labs, testing & monitoring
Your physician determines the final testing requirements for Tirzepatide after reviewing your intake. The panels below are what is commonly reviewed for this therapy — they are educational guidance, not a fixed requirement.
Bloodwork status
Baseline Labs Generally Required
Commonly reviewed at baseline
- A1c and fasting glucose
- Comprehensive metabolic panel (CMP)
- Lipid panel
- Thyroid panel (TSH)
- Pregnancy status where applicable
Follow-up & monitoring
Each dose escalation is reviewed for tolerance, with weight trend and A1c reassessed at roughly 12-week intervals.
Who may not be a candidate
- Pregnancy or nursing
- Active malignancy without oncology clearance
- Known hypersensitivity to the preparation
- Personal or family history of medullary thyroid carcinoma or MEN2
- History of pancreatitis
- Active gastroparesis
Medication interactions
Your physician reviews all prescriptions, supplements, and over-the-counter medications during intake before anything is prescribed.
Safety
Safety & considerations
Compounded tirzepatide is not an FDA-approved product and is prepared for an individual patient pursuant to a valid prescription. Gastrointestinal effects — nausea, constipation, reflux, early fullness — are the most frequently reported and are managed with titration pace. Not appropriate with a personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, active gastroparesis, or during pregnancy or nursing.
Regulatory status: Compounded. Evidence level: Established. Eligibility, dosing, laboratory requirements, and follow-up care are determined exclusively by a licensed physician after review of your history.
Physician reviewed
Every protocol is approved by a licensed physician.
503A compounded
Prepared by licensed US compounding pharmacies.
Patient-specific Rx
Prescriptions are issued in your name only.
No membership
No concierge fee and no subscription to browse or begin.